CervoMed (CRVO) Stock Overview
A a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CRVO Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
CervoMed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.08 |
| 52 Week High | US$16.94 |
| 52 Week Low | US$1.92 |
| Beta | -6.48 |
| 1 Month Change | -18.71% |
| 3 Month Change | 0% |
| 1 Year Change | 236.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 6.46% |
Recent News & Updates
Recent updates
Is CervoMed (NASDAQ:CRVO) In A Good Position To Invest In Growth?
Nov 19
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
Mar 22CervoMed Inc.'s (NASDAQ:CRVO) Price Is Right But Growth Is Lacking
Mar 12CervoMed Inc.'s (NASDAQ:CRVO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Nov 19We're Not Very Worried About CervoMed's (NASDAQ:CRVO) Cash Burn Rate
Aug 24Companies Like CervoMed (NASDAQ:CRVO) Are In A Position To Invest In Growth
Dec 07Shareholder Returns
| CRVO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.3% | 1.1% | 1.3% |
| 1Y | 236.7% | 26.4% | 15.8% |
Return vs Industry: CRVO exceeded the US Biotechs industry which returned 26.4% over the past year.
Return vs Market: CRVO exceeded the US Market which returned 15.8% over the past year.
Price Volatility
| CRVO volatility | |
|---|---|
| CRVO Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CRVO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CRVO's weekly volatility has decreased from 27% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 15 | John Alam | www.cervomed.com |
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders.
CervoMed Inc. Fundamentals Summary
| CRVO fundamental statistics | |
|---|---|
| Market cap | US$74.76m |
| Earnings (TTM) | -US$25.58m |
| Revenue (TTM) | US$6.16m |
Is CRVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRVO income statement (TTM) | |
|---|---|
| Revenue | US$6.16m |
| Cost of Revenue | US$23.07m |
| Gross Profit | -US$16.91m |
| Other Expenses | US$8.67m |
| Earnings | -US$25.58m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.77 |
| Gross Margin | -274.58% |
| Net Profit Margin | -415.36% |
| Debt/Equity Ratio | 0% |
How did CRVO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/28 09:18 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CervoMed Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tyler Bussian | Brookline Capital Markets |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |